A new polymer-based drug delivery system for mRNA and other nucleic acids has won the CPHI Excellence in Pharma Award in the category “Packaging and Drug Delivery”.
The system was developed by Evonik Health Care together with researchers at Stanford University.
Developed together with Professors Robert Waymouth, Paul Wender and Ronald Levy from the University of Stanford in the US, the prize-winning polymer-based platform complements Evonik’s existing portfolio of lipid-based drug delivery technologies, including lipid nanoparticles (LNPs).
The annual CPHI Excellence in Pharma Awards were established in 2004 to celebrate cross-industry innovators driving the industry forward. In 2022, there were more than 180 entries in 10 categories. The award was presented at the CPHI pharmaceutical trade show in Frankfurt on November 1, 2022.
Earlier this year, Evonik announced a joint investment with the US Government of US$220 million to build one of the world’s largest lipid production plants at its site in Tippecanoe, Indiana. A new plant to produce customised lipids at Evonik’s Hanau site is also scheduled to come on stream as early as the beginning of 2023.
